gms | German Medical Science

28. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

24. bis 27.11.2004, Hannover

Influence of Different Antihypertensive Treatment Strategies on Weight Reduction with Sibutramine vs Placebo

Einfluß einer antihypertensiven Differentialtherapie auf das Gewichtsverhalten bei adipösen Patienten unter Sibutraminbehandlung versus Placebo

Meeting Abstract (Hypertonie 2004)

Suche in Medline nach

  • presenting/speaker J. Scholze - Charité - Universitätsmedizin Berlin (Berlin, D)
  • presenting/speaker E. Grimm - Charité - Universitätsmedizin Berlin (Berlin, D)
  • presenting/speaker D. Herrmann - Charité - Universitätsmedizin Berlin (Berlin, D)

Hypertonie 2004. 28. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Hannover, 24.-27.11.2004. Düsseldorf, Köln: German Medical Science; 2005. Doc04hochP89

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hoch2004/04hoch089.shtml

Veröffentlicht: 10. August 2005

© 2005 Scholze et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Aim: To investigate interaction of different combinations of two antihypertensive drugs on sibutramine(Sib)-induced weight reduction and influence on blood pressure (bp) in non-adequately controlled obese hypertensive patients.

Methods: Randomized, placebo-controlled, multicenter study in 169 hypertensive patients with a BMI= 27-<45kg/m2 who were randomly assigned to receive one of three combinations of two antihypertensive agents (D:5mg felodipine/5mg ramipril, B:95mg metoprolol/12.5mg HCT, T:180mg verapamilSR/2mg trandolapril). After two weeks of antihypertensive treatment patients with grade 1 hypertension (140-159/90-99mmHg) were assigned to receive treatment with Sib 10/15 mg or placebo (Plac) for 16 weeks. Patients were controlled for body weight, bp (office, 24h-ABPM) and quality of life (QoL).

Results: Weight reduction in Plac patients was 1.1% for all antihypertensive combinations. Sib patients exhibited a significantly reduced body weight. Weight reduction was greatest for T and D (-6.0 and -6,7%, respectively) and somewhat less for the betablocker/HCT combination (-3.3%). Office bp was reduced in both groups (Sib: -5.6/-0.2, Plac: -5.2/-2.8mmHg) while 24h-ABPM levels were unchanged (Sib: -0.1/2.4, Plac: -1.2/-0.7mmHg). Heart rate significantly increased by +5.3 and decreased by 2.8 beats/min in Sib and Plac patients, respectively with no relevant differences between the antihypertensive treatment groups. QoL improvement was significantly greater in Sib than in Plac patients; the smallest increase was seen in B.

Conclusions: Sib significantly reduced body weight in obese hypertensive patients. The betablocker/HCT based strategy produced the smallest reduction. In addition, Sib has no negative impact on bp.